Scholarlink

Background <p>Renal cell carcinoma (RCC), the most common solid tumor of the kidney, accounts for approximately 3% of all malignancies and has a higher incidence in Western countries. The current frontline treatment for metastatic RCC (mRCC) relies on immune checkpoint inhibitors (ICIs), alone or in combination with tyrosine kinase inhibitors (TKIs). Although initially effective, these therapies often lose efficacy due to the emergence of drug resistance, which severely limits long-term patient survival. Among the mechanisms exploited by cancer cells to evade treatment, autophagy has emerged as a key contributor. Here, we explore the role of autophagy in driving therapeutic resistance in kidney cancer.</p> Results <p>We demonstrate that metastatic RCC tissues display markedly higher levels of LC3 compared to matched primary tumors, suggesting a role of autophagy in disease progression. Pharmacological inhibition of autophagy with desmethylclomipramine (DCMI), a tricyclic antidepressant, significantly impairs RCC cell proliferation, invasion, and migration while promoting apoptosis. Notably, combining DCMI with the TKI Sunitinib enhances antitumor efficacy beyond either treatment alone, through a mechanism involving the p53/p21 pathway.</p> Conclusion <p>Our findings underscore the importance of autophagy in the progression and therapeutic resistance of renal carcinoma. Targeting autophagy, particularly in combination with TKIs, may offer a promising strategy to overcome drug resistance and improve outcomes in patients with mRCC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Autophagy inhibition potentiates anti-cancer activity of Sunitinib in kidney cancer cells

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月15日

查看全文
  • Simone Patergnani,
  • Pietro Zampieri,
  • Nicoletta Bianchi,
  • Carmelo Ippolito,
  • Roberta Gafà,
  • Giovanni Lanza,
  • Mariusz R. Wieckowski,
  • Paolo Pinton,
  • Gianluca Aguiari

摘要

Background

Renal cell carcinoma (RCC), the most common solid tumor of the kidney, accounts for approximately 3% of all malignancies and has a higher incidence in Western countries. The current frontline treatment for metastatic RCC (mRCC) relies on immune checkpoint inhibitors (ICIs), alone or in combination with tyrosine kinase inhibitors (TKIs). Although initially effective, these therapies often lose efficacy due to the emergence of drug resistance, which severely limits long-term patient survival. Among the mechanisms exploited by cancer cells to evade treatment, autophagy has emerged as a key contributor. Here, we explore the role of autophagy in driving therapeutic resistance in kidney cancer.

Results

We demonstrate that metastatic RCC tissues display markedly higher levels of LC3 compared to matched primary tumors, suggesting a role of autophagy in disease progression. Pharmacological inhibition of autophagy with desmethylclomipramine (DCMI), a tricyclic antidepressant, significantly impairs RCC cell proliferation, invasion, and migration while promoting apoptosis. Notably, combining DCMI with the TKI Sunitinib enhances antitumor efficacy beyond either treatment alone, through a mechanism involving the p53/p21 pathway.

Conclusion

Our findings underscore the importance of autophagy in the progression and therapeutic resistance of renal carcinoma. Targeting autophagy, particularly in combination with TKIs, may offer a promising strategy to overcome drug resistance and improve outcomes in patients with mRCC.